Predicting RNFL Thinning in Glaucoma
Baseline Influencers of Vision and Edema in Proliferative DR: Ranibizumab Versus PRP
Factors Associated With Graft Success in the Cornea Preservation Time Study
Vascular Safety Profile of Ranibizumab
Cataract Surgery Alters Corneal Biomechanics and IOP
Is It Time to Reclassify Large Macular Holes?
Five-Year Outcomes of Randomized Trial Comparing Laser with Ranibizumab for PDR
Racial Differences in Long-Term Trabeculectomy Outcomes
Fellow-Eye Treatment of Open-Angle Glaucoma: CIGTS Results
Conjunctivitis Secondary to Dupilumab Treatment of Atopic Dermatitis
Ophthalmic NSAIDs for Corneal Dystrophy Caused by SLC4A11 Mutation
See the impact of this rare autoimmune disease.
Read more about TEPEZZA.
TEPEZZA is a trademark owned by or licensed to Horizon.© 2021 Horizon Therapeutics plc P-TEP-01183 08/21
Public & Patients
Museum of the Eye